Valuation: Elutia Inc.

Market Cap 42M 36.8M 34.16M 31.39M 59.15M 4.05B 60.02M 407M 159M 1.98B 158M 154M 6.85B P/E 2026 *
-1.58x
P/E 2027 * -1.83x
Enterprise Value 42M 36.8M 34.16M 31.39M 59.15M 4.05B 60.02M 407M 159M 1.98B 158M 154M 6.85B EV / Sales 2026 *
3.5x
EV / Sales 2027 * 3.21x
Free-Float
85.23%
Yield 2026 *
-
Yield 2027 * -
1 day-1.89%
1 week-2.91%
Current month-4.86%
1 month-6.80%
3 months-18.96%
6 months-7.72%
Current year+34.55%
1 week 0.88
Extreme 0.88
1
1 month 0.88
Extreme 0.88
1.07
Current year 0.6
Extreme 0.6019
1.38
1 year 0.5
Extreme 0.5
2.5
3 years 0.5
Extreme 0.5
5.24
5 years 0.5
Extreme 0.5
9.76
10 years 0.5
Extreme 0.5
18.2
Manager TitleAgeSince
Chief Operating Officer 52 -
Chief Executive Officer 54 2022-06-20
Director of Finance/CFO 58 2020-09-27
Director TitleAgeSince
Chairman 65 2015-10-31
Director/Board Member 54 2015-10-31
Director/Board Member 70 2020-08-31
Date Insider Type Main position Quantity % Market Cap.
6/21/26 Fiscal year

Founder

53,010 0.1199%
6/11/26 Free

Director

106,393 0.2407%
6/11/26 Free

Director

106,393 0.2407%
Change 5-day change 1-year change 3-year change Capi.($)
-1.89%-2.91%-55.62%-61.80% 42M
-3.56%-2.00%+16.09%-10.45% 68.69B
-0.25%+4.65%+40.39%+196.63% 52.97B
-1.65%+37.20%+37.20%+37.20% 43.61B
-2.83%-4.08%-53.81%-55.84% 40.75B
-2.67%+0.25%+54.67%-28.61% 29.99B
-2.67%-14.95%+77.42%-52.79% 23.67B
-1.36%+0.61%+68.06%+82.46% 23.45B
+0.11%+2.44%+4.06%+181.25% 20.46B
-0.39%+2.03%+72.19%+122.26% 16.66B
Average -1.70%+1.02%+26.07%+41.03% 32.03B
Weighted average by Cap. -1.94%+1.22%+28.18%+45.62%

Financials

2026 *2027 *
Net sales 12M 10.51M 9.76M 8.97M 16.9M 1.16B 17.15M 116M 45.51M 567M 45.05M 44.08M 1.96B 13.1M 11.48M 10.66M 9.79M 18.45M 1.26B 18.72M 127M 49.68M 619M 49.18M 48.12M 2.14B
Net income -25.4M -22.26M -20.66M -18.99M -35.78M -2.45B -36.3M -246M -96.33M -1.2B -95.35M -93.29M -4.14B -22.4M -19.63M -18.22M -16.74M -31.55M -2.16B -32.01M -217M -84.96M -1.06B -84.09M -82.28M -3.65B
Net Debt - -
Logo Elutia Inc.
Elutia Inc. is a commercial-stage company, which has developed a portfolio of products using both human and porcine tissue. Its portfolio of products spans the Women’s Health and Cardiovascular markets. In Women’s Health, it offers SimpliDerm, a novel biological matrix that leverages the inherent science of natural healing processes. SimpliDerm's design uses human-based hydrated acellular dermal matrix (ADM), which mitigates inflammation and enhances tissue incorporation. In Cardiovascular, it sells its specialized porcine small intestine submucosa for use as an intracardiac and vascular patch, as well as for pericardial reconstruction. In addition, its TYKE product is designed for use in the neonatal patient population. It is focused on advancing NXT-41x, a biomatrix that directly addresses the root causes of reconstruction infections following mastectomy. NXT-41x combines biologics and extended antibiotic release to provide protection while supporting tissue regeneration.
Employees
26
Date Price Change Volume
26-07-22 US$0.9320 -1.89% 87,425
26-07-21 US$0.9500 +2.14% 49,769
26-07-20 US$0.9301 -2.09% 26,367
26-07-17 US$0.9500 0.00% 251,437
26-07-16 US$0.9500 -1.03% 831,926
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.9500USD
Average target price
5.000USD
Spread / Average Target
+426.32%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ELUT Stock